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Despite increasing concerns over inappropriate use of antibiotics in medicine and food production, population-level resistance
transfer into the human gut microbiota has not been demonstrated beyond individual case studies. To determine the
‘‘antibiotic resistance potential’’ for entire microbial communities, we employ metagenomic data and quantify the totality of
known resistance genes in each community (its resistome) for 68 classes and subclasses of antibiotics. In 252 fecal metagenomes
from three countries, we show that the most abundant resistance determinants are those for antibiotics also used in animals
and for antibiotics that have been available longer. Resistance genes are also more abundant in samples from Spain, Italy, and
France than from Denmark, the United States, or Japan. Where comparable country-level data on antibiotic use in both
humans and animals are available, differences in these statistics match the observed resistance potential differences. The results
are robust over time as the antibiotic resistance determinants of individuals persist in the human gut flora for at least a year.
[Supplemental material is available for this article.]
When exposed to antibiotic compounds, bacteria evolve resistance
mechanisms. These include polymorphisms in antibiotic targets
that reduce vulnerability, as well as genes encoding efflux systems,
drug modifiers, or proteins that fortify target sites (Wright 2007;
Davies and Davies 2010). Resistance determinants can be trans-
ferred via mobile genetic elements, such as plasmids, prophages,
or transposons, allowing horizontal transfer within and between
bacterial species (Davies and Davies 2010), particularly in envi-
ronments such as the gut microbiome (Salyers et al. 2004; Schjørring
and Krogfeldt 2011; Smillie et al. 2011), and have collectively been
dubbed the antibiotic resistome (Wright 2007; Marshall and Levy
2011). The transfer of resistance genes into the gut can come from
diverse environments, for example, from soil bacteria (Forsberg
et al. 2012). Previous studies have explored the pig gut resistome
(Looft et al. 2012), as well as that of two human donors (Sommer
et al. 2009), but population-scale studies are still lacking. Since
antibiotics are widely used in medicine (Goossens et al. 2005) and
food production (Barton 2000; Davies and Davies 2010; Marshall
and Levy 2011; Aarestrup 2012), understanding the variation of
the resistome within the population is crucial.
Results
To assess the resistome of an individual or a group of individuals,
we collected 380 known antibiotic resistance determinants (Liu
and Pop 2009) for 68 broad or narrow classes and subclasses (which
share chemical structure and resistance mechanisms) (see Sup-
plemental Methods) of antibiotics, accounted for known cross-
resistances (Supplemental Table S1; Supplemental Fig. S1), and
identified homologs in public metagenomes derived from 252
fecal samples of 207 individuals from three countries (6.37 Gbp,
per individual on average; see Methods). To compare their relative
abundances across samples, we down-sampled each individual to
726 Mbp, the size of the smallest sample, and found resistance
genes for 50 of the 68 antibiotic classes and subclasses in our cohort
(Fig. 1A; Supplemental Fig. S2), at an average of 21 per sample.
We first analyzed some general trends such as the connection
between use in animal husbandry and the spread of resistance,
previously suggested from studies of one or a few antibiotics at
a time (Levy et al. 1976; Holmberg et al. 1984; Hummel et al. 1986;
Bager et al. 1997; Fey et al. 2000).We observe a clear and significant
increase in resistance gene abundance both for antibiotics ap-
proved for animal use by the U.S. FDA (Fig. 1B) and for older
antibiotics that have been longer in the market (Kruskal-Wallis
P < 2.2 3 1016 in both cases) (Fig. 1C). These effects are inde-
pendent (Supplemental Fig. S3) and hold even when controlling
for differences in number of genes active against each antibiotic
class or subclass (Supplemental Figs. S4, S5), as well as separately
for different countries (Supplemental Fig. S6) and at varying de-
grees of down-sampling (Supplemental Fig. S7). Thus, we conclude
that the use of antibiotics in animals contributes to resistance de-
velopment in human commensal bacteria.
To screen the cohort for differences in resistance adaptations
between gut samples from different countries, we developed a
measure for the ‘‘antibiotic resistance potential’’ of a microbial
community based on the abundance of its resistance genes rela-
tive to its species composition (see Methods). We then determined
the antibiotic resistance potential in 142 American (The Human
Microbiome Project Consortium 2012; Schloissnig et al. 2012), 39
Spanish (Qin et al. 2010), and 71 Danish (Qin et al. 2010) samples
that were previously Illumina-sequenced and tested for influence
of possible confounding factors (disease status, gender, enterotype
[Arumugam et al. 2011], BMI, or geographic origin of samples) (see
Supplemental Figs. S8–S12), but we only found an effect of entero-
types, for which we controlled (see Methods). We tested each
antibiotic for significant country differences in resistance potential
at a false-discovery rate (FDR) of 5%, using an FDR correction robust
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to the interdependencies of the resistance potentials (Benjamini
and Yekutieli 2001). In almost every such case, the Spanish
samples exhibit both higher antibiotic resistance gene penetra-
tion in the population and higher relative resistance potential
(Fig. 2A) than either the Danish or U.S. samples. The U.S. and
Danish samples are similar, though the U.S. individuals have
somewhat higher resistance potentials for macrolides, lincosa-
mides, and streptogramins, common agricultural growth pro-
moters (Barton 2000), as well as for cephalosporins, which are used
prophylactically in food animals. The Danish antibiotic resistome,
on the other hand, has a relative bias to-
ward bacitracin and vancomycin and
to a lesser extent toward streptomycin,
spectomycin, and chloramphenicol. No-
tably, a vancomycin analog (avoparcin)
has been previously administered to ani-
mals in Europe but not in the United
States (Barton 2000), and was subse-
quently banned as its use was linked to a
rapid European increase in vancomycin-
resistant enterococci (VRE) (Kjerulf et al.
1996; Bager et al. 1997; Barton 2000;
Aarestrup 2012). The presence of VRE in
Danish fecal samples has previously been
linked to imported turkey meat (Agersø
et al. 2008). The resistance determinant
(vanA) reported in that study was not
found in any of the samples analyzed in
the present work, but instead other van-
comycin resistance gene families were
detected, with the genes of the vanG
vancomycin resistance operon most of-
ten being enriched. We also verified that
these trends hold independently of re-
sistance mechanism and found that re-
sistance genes that can increase cross-
protection within the community through
antibiotic modification shows the most
extreme country bias (Fig. 2B; Supple-
mental Figs. S13–S15).
To better understand the observed
country differences, we included addi-
tional smaller metagenomes from other
European countries. Since these were
generated with different sequencing tech-
nologies, and also to allow testing of the
robustness of the results, we down-sampled
the Illumina data further and included ad-
ditional Sanger or 454 Life Sciences (Roche)
sequencing data sets from all three
countries analyzed above (Fig. 2C; Sup-
plemental Fig. S16; Arumugam et al. 2011;
Yatsunenko et al. 2012). Simulations show
that neither down-sampling to 50Mbp per
sample nor reducing the number of sam-
ples to four eliminates the country differ-
ences we see (Supplemental Figs. S17–S19).
Thus, at the price of lower resolution, we
could include smaller metagenomes from
individuals of several other countries (Fig.
2C; Supplemental Fig. S16) and found that
individuals from two additional southern
European countries, Italy and France, have resistance potentials
comparable to those of Spanish individuals (Fig. 2C).
A linkage of fecal carriage of resistant bacteria to human an-
tibiotic consumption has been demonstrated (Levy et al. 1988;
Barbosa and Levy 2000), and previous comparative studies have
also revealed higher human antibiotic consumption in southern
Europe than in Denmark (Fig. 2D, top and bottom left; Goossens
et al. 2005; Borg 2012), as well as higher proportions of resistant
bacteria isolated from food-producing animals (Fig. 2D, bottom
right; de Jong et al. 2012), suggesting greater use of antibiotics in
Figure 1. (A) Resistance gene penetration is higher for antibiotics approved for use in animals or with
analogs that have such approval. Shown is the fraction of 252 gut samples where at least one resistance-
associated gene is fully covered by sequencing, for members of 66 classes or subclasses (with the most
narrow subclasses being single compounds, see Methods) of antibiotics represented in the Antibiotic Re-
sistance Genes Database (ARDB) (Supplemental Table S1), and for which the time since introduction and
animal usage approval informationwas available. The colors of the bars representwhether or not animal use
has been approvedby theU.S. FDA according to the ‘‘Green Book’’ database (Shields 2009), andwhether or
not such use is approved for any close analogs of each antibiotic. (B) Antibiotics approved for animal use
have significantly (Kruskal-Wallis test for categories having same median, P < 2 3 1016) higher resistance
potential in our data set. The figure shows base coverage per site for resistance genes assigned to categories
based on animal use approval. To control for different numbers of known resistance genes targeting each
antibiotic (Supplemental Table S1), the average over all resistance gene families are taken. The box plots
represent the 252 Illumina samples. (C ) Antibiotics that have been longer in use have significantly (Kruskal-
Wallis test for categories having samemedian, P < 23 1016) higher resistance potential in our data set. The
figure shows base coverage per site for resistance genes assigned to categories based on how long the
antibiotics they protect against have been in use, estimated from the time since first publication for each
compound. If an antibiotic has analogs, the age of the oldest analog is used to account for cross-resistances
(Supplemental Table S1). The box plots represent the 252 Illumina samples.
1164 Genome Research
www.genome.org
Forslund et al.
 Cold Spring Harbor Laboratory Press on May 29, 2018 - Published by genome.cshlp.orgDownloaded from 
food production in southern Europe (fair comparisons are
presently only possible within Europe as there are no antibiotic
use or sales statistics available that were compiled in the same
way there and in the United States). Each of these country-level
measures of antibiotic exposure is positively correlated with the
median resistance potential of samples from these countries,
and despite data being available only for four countries, the cor-
relation between resistance potential and total outpatient anti-
biotic use is significant (Pearson r = 0.97, Bonferroni-corrected
P < 0.08).
To further investigate the effect of agricultural use of antibi-
otics on the human gut resistance potential, we collected data on
2009 veterinary antibiotic sales in Denmark and Spain and nor-
malized by livestock biomass (Supplemental Table S2). We then
modeled resistance potential using a mixed-effects framework.
Biomass-normalized antibiotic exposure significantly (P < 0.023)
increases median resistance potential across the 11 antibiotic
classes tested in this manner (Supplemental Fig. S20).
The higher transmission of resistance genes for antibiotics
used in food-producing animals inMediterranean countriesmight
Figure 2. (Legend on next page)
Antibiotic use impact on the human gut resistome
Genome Research 1165
www.genome.org
 Cold Spring Harbor Laboratory Press on May 29, 2018 - Published by genome.cshlp.orgDownloaded from 
also be linked to diet as it has been reported that raw or cured food
products, common in southern Europe (aged cheeses, cured sau-
sages, olive fermentations), can carry high bacterial loads (Franz
et al. 2011). Indeed, we find that resistance was detected in fer-
mented food products (see Supplemental Information) for some of
the antibiotics where the resistance potential also differs most
between countries.
Although based on smaller data sets, generated using different
sequencing technologies, we also measured the antibiotic resis-
tance potential in Japanese and Malawian individuals (Fig. 2C;
Supplemental Fig. S16). The Japanese cohort (Kurokawa et al. 2007)
has an overall antibiotic resistance potential similar to that of U.S.
and Danish donors, whereas the Malawian cohort (Yatsunenko
et al. 2012), representing a rural population in a nonindustrialized
nation, has an even higher overall resistance potential than those
of southern European countries. The Malawian samples are highly
skewed toward cephalosporin and tetracycline resistance genes
(data not shown) when compared to the rest of the data set. This
might indicate extensive use of old, broad-spectrum antibiotics,
a known problem in many developing countries (Hart and Kariuki
1998; Nordberg et al. 2005), although this hypothesis would need
to be further validated with more samples and antibiotic con-
sumption information.
To assess persistence of individual resistomes over time, we
utilized a subset of 43U.S. samples (TheHumanMicrobiomeProject
Consortium2012) taken at two or three separate time points from
each donor. Samples from the same individual are, on average,
more similar in their antibiotic resistance potential than samples
from different individuals, and this similarity does not decrease
noticeablywith time (Fig. 3). This is consistent with earlier research
on individual antibiotics (Shoemaker et al. 2001; Salyers et al. 2004;
Johnsen et al. 2011) showing that resistance determinants, once in-
troduced into the microbial flora, can persist for a long time at low
abundances, which might also explain the high vancomycin re-
sistance potential in the Danish population despite its animal-use
analog being banned since 1995 (Aarestrup 2012).
We did not discriminate here between pathogens and com-
mensals but rather considered the gut microbiome in its entirety
and as a common antibiotic resistance reservoir (Barton 2000;
Goossens et al. 2005), which potentially enables pathogens to
become resistant through lateral gene transfer or enables rare re-
sistant commensals or opportunistic pathogens to gain dominance
in the case of antibiotic treatment. This can disturb normal gut
function, such as in antibiotic-associated diarrhea and Clostridium
difficile–associated symptoms (Gerding 2004). As our approach
characterizes the whole of this reservoir, it might thus also allow
making individualized recommendations on which antibiotics to
avoid. Formany antibiotics, some individuals have extremely high
resistance potentials. For example, for vancomycin, tigecycline,
chloramphenicol, and several aminoglycosides, more than 20 in-
dividuals in our data set have a resistance potential 10-fold higher
than the population median, which might indicate the presence
of resistant strains which in turn could transfer this resistance
further upon antibiotic exposure of the community (Supple-
mental Table S3). One U.S. individual has on average more than
30 times the population median resistance potential for nine
aminoglycosides due to antibiotic modification systems. Another
extreme case is a Spanish individual with more than 30 times the
population median resistance potential for cephalosporins and
more than 100 times the population median resistance potential
for macrolides, lincosamides, and streptogramin B. While our se-
quence-based analysis method only captures the potential for
antibiotic resistance, studies show high correlation between the
presence of resistance determinants and results of in vitro sus-
ceptibility tests (Martineau et al. 2000; Zhu et al. 2007; Eitel et al.
2012), suggesting clinical utility of these findings.
Discussion
We have measured the content and variation of the human gut
antibiotic resistome across large-scale data sets from different
populations. While our analysis can detect only the potential for
resistance stemming from previously characterized resistance de-
terminants, and only to the extent that the target spectrumof each
such gene is correctly annotated, it is based on a comprehensive
collection of resistance gene families and therefore at least unlikely
to miss any major trends.
Comparing different antibiotics, we have shown that re-
sistance gene abundance and penetration on average are higher for
drugs used in animals, even when compensating for differences
Figure 2. (A) Geographic differences in antibiotic resistance potential. For several antibiotics, strong and significant country differences in the respective
resistance gene penetration and taxonomy-adjusted resistance potential are observed, whereby mostly those of Spanish individuals are higher than those
of U.S. or Danish individuals. Antibiotics with significantly different resistance distribution between Danish (N = 71), Spanish (N = 39), and American (U.S.)
(N = 142) samples are displayed, with general resistance to broad classes represented by including ‘‘miscellaneous’’ or ‘‘generic’’ members of those classes
subject only to resistance from the genes with the more general annotation (see Methods). To account for cross-resistances, a multiple testing correction
procedure was chosen which does not assume independence between the resistance potentials of different antibiotics (Benjamini and Yekutieli 2001).
Most antibiotics that show significant country differences are approved for animal use or have analogs that are, although this is not a significant enrichment
over the full set of antibiotics. All samples were stochastically down-sampled to the size of the smallest sample (;726Mbp) prior to the analysis. The lines/
triangle markers represent the fraction of samples from each country where at least one resistance gene is fully covered by sequencing. The dot/bar
markers represent median and 25%/75% quartiles for resistance potential, measured as the total resistance gene abundance for each antibiotic relative to
the amount of genetic material in each sample that comes from species where any resistance genes are found. (B) Significant country differences are seen
separately for antibiotic resistance genes acting by different mechanisms (Kruskal-Wallis test for countries having same median, P [drug modification] <
1.98 3 108, P [efflux] < 6.68 3 109, P [target protection] < 4.17 3 105). The figures show base coverage per site for resistance genes assigned to
categories based on whether they operate by modifying antibiotic molecules, protecting cellular target sites, or exporting antibiotic molecules from
bacterial cells. The average is taken over the resistance genes in each category, with the boxes representing the 142 American, 71 Danish, and 39 Spanish
samples, respectively. (C ) The higher resistance potential in Spanish than in Danish samples is also seen in other samples from southern Europe (France,
Italy). The distributions are significantly different between these four countries (Kruskal-Wallis P < 1.073 105). Results are broadly in agreement between
different sequencing platforms (see Supplemental Text). The samples were stochastically down-sampled to 50Mbp prior to the analysis. (D) Gut resistance
potential coincides with antibiotic exposure when comparing Denmark with southern Europe. The bar charts show comparative statistics from the
literature: outpatient antibiotic consumption in 2008 from the same four countries (European Surveillance of Antimicrobial Consumption [ESAC] survey)
(Goossens et al. 2005) measured in defined daily doses (DDDs) per 1000 inhabitants, frequency of antibiotic resistance in bacterial isolates from
slaughterhouses in a 2011 comparative study (de Jong et al. 2012), and fraction of approximately 1000 respondents in each country that had taken
antibiotics during the last 12mo (Borg 2012). Resistance potential correlates significantly with outpatient antibiotic use (Pearson r = 0.97; t-test [N = 4, df =
2]; Bonferroni-corrected P < 0.08).
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in how many resistance genes are known. This is consistent with
expectations from previous research into a ‘‘farm-to-fork’’ con-
nection (Marshall and Levy 2011).
By analyzing a large cohort of individuals, we can compare
their resistomes and point to resistance potentials elevated beyond
what is expected from themicrobial community composition. The
determination of individual profiles of resistance potentials, which
can be increased for particular antibiotics, may eventually find use
in clinical settings.
Beyond individual variation, we see robust differences in gut
resistance potential between countries. Presently available data
sets lack individual-levelmetadata on diet or antibiotic use history,
and so the causes for these differences cannot yet be conclusively
determined. However, we note that the observed differences
largely coincide in scope and directionwith country-level statistics
of veterinary and human antibiotic use, for countries where com-
parable statistics are available. While future studies need to quan-
tify the individual contributing factors, the causes suggested by
this and previous studies are all, in principle, open to intervention:
policies, use practices, or food consumption habits, whereby it
remains to be seen whether the observed persistence over time
of the already acquired individual resistomes can be overcome too.
This outcome of our global, metagenomic-based approach,
mapping variation within and between populations and covering
a vast range of antibiotics, should provide a profound molecular
basis for the ongoing debate on the appropriate use of antibiotics
in agriculture and medicine. While interpretation of our results
is limited by availability of comparable antibiotic exposure data
on both an individual and a national level, we are confident that
further efforts in large-scale antibiotic resistance surveillance and
molecular characterization of resistance genes will eventually al-
low the resistance potentials introduced in this study to be mea-
sured at an increased resolution.
Methods
Stool samples were previously taken from volunteers as part of the
MetaHIT (71 Danish and 39 Spanish samples) (Qin et al. 2010) and
HMP (139 U.S. samples) (The Human Microbiome Project Con-
sortium 2012) projects, with an additional three U.S. samples from
another project (Schloissnig et al. 2012), and sequenced as part of
other projects using Illumina technology (Supplemental Table S4).
A collection of 3496 fully sequenced reference genomes was
compiled (Supplemental Table S5), and a catalog of gut meta-
genomic reference genes was generated from the stool samples.
The MOCAT pipeline (Kultima et al. 2012) was used to map reads
to the set of reference genes, producing gene abundance estimates
(Supplemental Table S6). Simulations were carried out to verify
that no artifacts were introduced by this pipeline (Supplemental
Table S7). Species composition of the samples was estimated using
a curated set of 40 marker genes that are usually found in single
copy in microbial genomes (Supplemental Table S8). Samples were
stochastically down-sampled by randomly discarding sequenced
bases in short read-sizedblocks. Previously described Sanger and454
Life Sciences (Roche) samples (Kurokawa et al. 2007; Arumugam
et al. 2011; Yatsunenko et al. 2012) were converted into the same
short-read format as the larger data set, and all samples were then
stochastically down-sampled to a common size of 50 Mbp, before
repeating the analysis.
To identify antibiotic resistance determinants, the ARDB ref-
erence protein collection (Liu and Pop 2009) was augmented with
homologs from the 3496 reference genomes, using family-specific
inclusion thresholds and, where available, gene symbol annota-
tion. These sequences were used to search the gut metagenomic
reference gene catalog to yield a set of resistance genes present in
the gut samples (Supplemental Tables S9, S10). These were further
curated by searching also the NCBI nonredundant database to
verify the top annotated matches were matched to the correct re-
sistance gene families. For each resistance gene family, its dis-
tribution among the reference genomes was determined (Sup-
plemental Tables S11, S12).
The resistance potential was defined as the average genome
fraction encoding resistance genes for a particular antibiotic or
category of antibiotics, across all bacteria in a sample that could
potentially carry such resistance genes, based on the known tax-
onomic ranges of these resistance gene families. This potential was
determined from the total number of bases sequenced from these
genes and species, respectively. To compensate for stochastic ef-
fects in the case of very small abundances of applicable species, the
resistance gene base count was down-sampled, separately for each
antibiotic, by randomly removing average read-sized blocks of
bases such that all samples analyzed have the same resulting pro-
portion of bases mapping to the carrier species. The ratio of the
down-sampled resistance gene base count to this ‘‘target number’’
of bases from potentially resistance-carrying species was taken
as the final resistance potential. Results were similar if raw ratios
were used instead of down-sampled (Supplemental Fig. S12). By
measuring resistance gene abundances relative to the pooled
abundances of potential carrier species, this taxonomy-adjusted
resistance potential aims to broadly disentangle, to the extent that
Figure 3. Antibiotic resistance potential persists over time in the human
gut flora for at least a year. For 43 U.S. individuals, two or three time
points were sampled (The HumanMicrobiome Project Consortium 2012).
Each interval (measured in days) between two sampled time points is
represented by a green dot. For each such pair of samples, they are
compared with respect to carriage of 99 resistance gene families from
ARDB that are detectable in the gut samples, using the Kendall t corre-
lation coefficient, following compensation for sequencing depth and dif-
ferences in species composition. The gray dots represent the average
correlation between either of the two samples and the remaining 137
HMP samples in the data set. Red markers show the Kendall t correlation
coefficient for genus-level taxonomic composition profiles. Vertical lines
connect values for each sample. Linear regression of similarity of same-
donor sample pairs with respect to the time interval yields no notable
decrease in resistance potential similarity within the time spans considered
here (R2 < 0.015). Previous studies (Costello et al. 2009; The Human
Microbiome Project Consortium 2012) have shown that the composition
of a person’s gut microbiome as a whole is self-similar during a year
compared with that of other people. In almost every case, resistance po-
tentials are better conserved than overall taxonomic composition.
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current metagenomic data allows, the effects of selection toward
higher relative prevalence of resistance determinants from the
effects of broad changes in gut microbial species composition.
Simulations show that a method not considering taxonomic com-
position in this manner will falsely conclude country differences,
whereas our resistance potential analysis will not (Supplemental
Table S13). The term ‘‘resistance potential,’’ rather than simply
‘‘resistance,’’ was chosen to reflect how differences in resistance
gene expression and regulation also affect phenotypic resistance
in vivo, in addition to the role the resistome plays.
Significant country differences in antibiotic resistance were
concluded if a likelihood-ratio test comparing a linear model of
the resistance potential with country and enterotype as inde-
pendent variables with a null model omitting country achieved
Benjamini-Hochberg-Yekutieli FDR # 5%.
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